The companies have agreed to an all-stock merger of equals transaction anticipated to close in the second half of 2016.
On May 3, 2016, IMS Health Holdings, a global healthcare information and technology services company, and Quintiles Transnational Holdings Inc., a pharmaceutical contract research organization (CRO), announced their plans to combine in an all-stock merger of equals transaction. The merged company will be called Quintiles IMS Holdings, Inc., the companies said in a press announcement.
Based on the closing of IMS Health and Quintiles common stock prices on May 2, 2016, the equity market capitalization of the joined companies is more than $17.6 billion and the enterprise value is more than $23 billion. Under the terms of the merger agreement, IMS Health shareholders will receive a fixed exchange ratio of 0.384 shares of Quintiles common stock for each share of IMS Health common stock.
Upon completion of the merger, IMS Health shareholders will own approximately 51.4% of the shares of the combined company on a fully diluted basis, and Quintiles shareholders will own approximately 48.6% of the combined company on a fully diluted basis. The transaction is subject to customary closing conditions, including regulatory approvals and approval by both IMS Health and Quintiles shareholders and is expected to close in the second half of 2016.
Source: IMS Health
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.